

# Curasight announces change in the Board of Directors

**Copenhagen, April 12, 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announces that the chairperson of the Board of Directors, Per Falholt, has today announced that he wishes to step down from the Board of Directors with immediate effect. Kirsten Drejer has been elected as the new chairperson of the Board of Directors.**

Per Falholt, the Chairperson of the Board of Directors, has notified Curasight that he wishes to step down for the Board of Directors with effect from today due to personal reasons.

In continuation of this, an extraordinary board meeting has been held, where the board has constituted itself with Kirsten Drejer as the new chairperson of the Board of Directors.

*“I would like to thank Per Falholt for his great contribution to Curasight since the very beginning. It has been a pleasure working together with Per Falholt over these years since the successful IPO back in 2020, and I wish him the very best. At the same time, it is with great pleasure that Kirsten Drejer steps up as the new Chairperson of the Board of Directors. Her vast experience in drug development focused on oncology, her knowledge of building biotech companies, and her success in raising capital and closing partnership deals in biotech and pharma will be of great value to Curasight going forward”,* says Ulrich Krasilnikoff, CEO.

Kirsten Drejer holds a PhD in pharmacology and has been involved in drug development throughout her career. She is probably best known as co-founder and CEO of Symphogen A/S for 16 years. During her leadership at Symphogen A/S, she raised more than 300 million EUR from prominent international investors, 250 million EUR in non-dilutive cash through partnerships and grew the company to become one of the most prominent biotech companies within oncology with more than 100 employees.

Kirsten Drejer serves currently as Vice Chair of the Board of Zealand Pharma A/S and holds a board position in Malin Corporation.

This disclosure contains information that Curasight is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 12-04-2024 11:58 CET.

**For more information regarding Curasight, please contact:**

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: [uk@curasight.com](mailto:uk@curasight.com)

[www.curasight.com](http://www.curasight.com)

**Curasight** is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE<sup>®</sup>) and Radioligand Therapy (uTREAT<sup>®</sup>) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle

and efficient treatment of multiple cancer types.